A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome

Pharmacotherapy

Volumn 34, Issue 3, 2014, Pages 279-290

  Dzierba, Amy L ^a   Abel, Erik E ^b   Buckley, Mitchell S ^c   Lat, Ishaq ^d  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c BANNER GOOD SAMARITAN MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Acute respiratory distress syndrome; Critical care; Pulmonary

Indexed keywords

CORTICOSTEROID; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN E; SEDATIVE AGENT;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; BLEEDING; DISEASE SEVERITY; DRUG APPROVAL; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; EXTRACORPOREAL OXYGENATION; HUMAN; HYPOXEMIA; KIDNEY INJURY; LOW DRUG DOSE; LUNG TOXICITY; METHEMOGLOBINEMIA; NEBULIZATION; NEBULIZER; OXYGENATION; PHASE 2 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; THROMBOCYTE AGGREGATION; TRACHEITIS; VASODILATATION;

ACUTE LUNG INJURY; ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CLINICAL TRIALS AS TOPIC; EPOPROSTENOL; HUMANS; NITRIC OXIDE; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84898043034     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1365     Document Type: Review

References (64)

1. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest 2008;133: 1120-7. (Pubitemid 351685515)
2. Bernard GR, Artigas A, Brigham KL, et al. The American- European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149: 818-24. (Pubitemid 24082248)
3. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307: 2526-33.
4. Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med 1995;332: 27-37.
5. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342: 1301-8.
6. Silversides JA, Ferguson ND. Clinical review: acute respiratory distress syndrome-clinical ventilator management and adjunct therapy. Crit Care 2012;29:225.
7. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342: 1334-49. (Pubitemid 30408719)
8. Murphy CV, Schramm GE, Doherty JA, et al. The importance of fluid management in acute lung injury secondary to septic shock. Chest 2009;136: 102-9.
9. Wiedemann HP, Wheeler AP, Bernard GR, et al., National Heart Lung and Blood Institute Acute Respiratory Distress Syndrome Clinical Trials Network. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354: 2564-75. (Pubitemid 43882352)
10. Shafeeq H, Lat I. Pharmacotherapy for acute respiratory distress syndrome. Pharmacotherapy 2012;32: 943-57.
11. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363: 1107-16.
12. Stapleton RD, Wang BM, Hudson LD, et al. Causes and timing of death in patients with ARDS. Chest 2005;128: 525-32. (Pubitemid 41140476)
13. Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005;353: 2683-95. (Pubitemid 41817717)
14. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 1999;91: 1090-121. (Pubitemid 29466545)
15. Bloch KD, Ichinose F, Roberts JD Jr, et al. Inhaled NO as a therapeutic agent. Cardiovasc Res 2007;75: 339-48. (Pubitemid 46961928)
16. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31: 891-901.
17. Buckley MS, Feldman JP. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy 2010;30: 728-40.
18. Schermuly RT, Pullamsetti SS, Breitenbach SC, et al. Iloprost- induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res 2007;8:4.
19. Olschewski H, Ghofrani HA, Schmehl T, et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000;132: 435-43. (Pubitemid 30149040)
20. Olschewski H, Rohde B, Behr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 2003; 124: 1294-304. (Pubitemid 37290038)
21. Olschewski H, Walmrath D, Schermuly R, et al. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996;124: 820-4. (Pubitemid 26128412)
22. Angus DC, Clermont G, Linde-Zwirble WT, et al. Healthcare costs and long-term outcomes after acute respiratory distress syndrome: a phase III trial of inhaled nitric oxide. Crit Care Med 2006;34: 2883-90. (Pubitemid 44808728)
23. Cuthbertson BH, Galley HF, Webster NR. Effect of inhaled nitric oxide on key mediators of the inflammatory response in patients with acute lung injury. Crit Care Med 2000;28: 1736-41. (Pubitemid 30428721)
24. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998; 26: 15-23. (Pubitemid 28028435)
25. Gerlach H, Keh D, Semmerow A, et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med 2003;167: 1008-15. (Pubitemid 36408167)
26. Lundin S, Mang H, Smithies M, et al. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med 1999;25: 911-9. (Pubitemid 29452535)
27. Mehta S, Simms HH, Levy MM, et al. Inhaled nitric oxide improves oxygenation acutely but not chronically in acute respiratory distress syndrome: a randomized, control trial. J Appl Res 2001;1: 73-84.
28. Michael JR, Barton RG, Saffle JR, et al. Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS. Am J Respir Crit Care Med 1998;157: 1372-80.
29. Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004;291: 1603-9. (Pubitemid 38552433)
30. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998;157: 1483-8.
31. Adhikari NK, Burns KE, Friedrich JO, et al. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 2007;334:779.
32. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxemic respiratory failure in children and adults. Cochrane Database Syst Rev 2003; CD002787.
33. Gerlach H, Rossaint R, Pappert D, et al. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993;23: 499-502. (Pubitemid 23243942)
34. Puybasset L, Rouby JJ, Mourgeon E, et al. Inhaled nitric oxide in acute respiratory failure: dose-response curves. Intensive Care Med 1994;20: 319-27. (Pubitemid 24190957)
35. Cuthbertson BH, Dellinger P, Dyar OJ, et al. UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs. American-European Consensus Conference on ALI/ARDS. Intensive Care Med 1997;23: 1212-8. (Pubitemid 28017785)
36. Samama CM, Diaby M, Fellahi JL, et al. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1995;83: 56-65.
37. Afshari A, Brok J, Moller AM, et al. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev 2010;7:CD002787.
38. Brown GC. Nitric oxide regulates mitochondrial respiration and cell functions by inhibiting cytochrome oxidase. FEBS Lett 1995;369: 136-9.
39. Camamo JM, McCoy RH, Erstad BL. Retrospective evaluation of inhaled prostaglandins in patients with acute respiratory distress syndrome. Pharmacotherapy 2005;25: 184-90. (Pubitemid 40223480)
40. Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med 2001;29: 57-62. (Pubitemid 32125775)
41. van Heerden PV, Barden A, Michalopoulos N, et al. Doseresponse to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000;117: 819-27. (Pubitemid 30152226)
42. Walmrath D, Schneider T, Pilch J, et al. Aerosolised prostacyclin in adult respiratory distress syndrome. Lancet 1993;342: 961-2. (Pubitemid 23305501)
43. Walmrath D, Schneider T, Pilch J, et al. Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis. Am J Respir Crit Care Med 1995;151: 724-30.
44. ley KA, Louzon PR, Lee J, et al. Efficacy, safety, and medication errors associated with the use of inhaled epoprostenol for adults with acute respiratory distress syndrome: a pilot study. Ann Pharmacother 2013;47: 790-6.
45. McMillen JC, Burke CF, Dhingra A, et al. Use of inhaled epoprostenol in patients with H1N1 influenza-associated acute respiratory distress syndrome: a case series. Ann Pharmacother 2011;45:e26.
46. van Heerden PV, Caterina P, Filion P, et al. Pulmonary toxicity of inhaled aerosolized prostacyclin therapy-an observational study. Anaesth Intensive Care 2000;28: 161-6. (Pubitemid 30201231)
47. Haraldsson A, Kieler-Jensen N, Wadenvik H, et al. Inhaled prostacyclin and platelet function after cardiac surgery and cardiopulmonary bypass. Intensive Care Med 2000;26: 188-94. (Pubitemid 30186593)
48. Datex-Ohmeda I. INOvent delivery system operational and maintenance manual CGA variant (2000). Publication 1605-0014-000.
49. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56: 600-12. (Pubitemid 37491711)
50. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 2003;56: 588-99. (Pubitemid 37491710)
51. O'Riordan TG, Greco MJ, Perry RJ, et al. Nebulizer function during mechanical ventilation. Am Rev Respir Dis 1992;145: 1117-22.
52. O'Riordan TG, Palmer LB, Smaldone GC. Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery. Am J Respir Crit Care Med 1994;149: 214-9. (Pubitemid 24066122)
53. Thomas SH, O'Doherty MJ, Fidler HM, et al. Pulmonary deposition of a nebulised aerosol during mechanical ventilation. Thorax 1993;48: 154-9. (Pubitemid 23057222)
54. De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg 2004;127: 1058-67. (Pubitemid 38451939)
55. Siobal MS, Kallet RH, Pittet JF, et al. Description and evaluation of a delivery system for aerosolized prostacyclin. Respir Care 2003;48: 742-53. (Pubitemid 47377822)
56. Sutcliffe N, McCluskey A. Simple apparatus for continuous nebulisation of prostacyclin. Anaesthesia 2000;55:405. (Pubitemid 30209484)
57. Flolan® (epoprostenol sodium) for injection. Prescribing information. Research Triangle Park, NC: GlaxoSmithKline, March 2011.
58. Veletri® (epoprostenol sodium) for injection. Prescribing information. South San Francisco, CA: Actelion Pharmaceuticals, March 2011.
59. Torbic H, Szumita PM, Anger KE, et al. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. J Crit Care 2013;28: 844-8.
60. Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;153: 991-6. (Pubitemid 26081651)
61. Bigatello LM, Hurford WE, Kacmarek RM, et al. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome. Effects on pulmonary hemodynamics and oxygenation. Anesthesiology 1994;80: 761-70. (Pubitemid 24128938)
62. Krafft P, Fridrich P, Fitzgerald RD, et al. Effectiveness of nitric oxide inhalation in septic ARDS. Chest 1996;109: 486-93. (Pubitemid 26058610)
63. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996;154: 1671-7. (Pubitemid 26424933)
64. Van Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS-a pilot study. Anaesth Intensive Care 1996;24: 564-8. (Pubitemid 26377305)